Monument Therapeutics is a spin out from Cambridge Cognition advancing small molecules paired with a digital biomarker through phase I clinical trials, to address significant challenges in central nervous system (CNS) drug discovery.

Neuroscience has the potential to be in the ’20s what oncology has been in the last decade
Status Active
Website https://monumenttx.com/
Category Biotech
Modality Small Molecule
Therapautics Area
Headquaters Cambridge, UK
Investment Portfolio Fund Investment
Co-Investors Catapult Ventures, Cambridge Angels and Meltwind